Dementia complex due to HIV disease and aging;Le complexe démentiel associé au VIH: Aspects particuliers chez les sujets âgés

Psychologie et NeuroPsychiatrie du Vieillissement

Volumn 5, Issue 3, 2007, Pages 193-207

  Moulignier, Antoine ^a  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

AIDS; Antiretroviral drugs; Brain; CD4; CD8; Cognitive impairment; Dementia; Elderly; Encephalitis; HAART; HIV; Immune reconstitution; Neurologic complications; Neuropsychology

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; BRAIN; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG PENETRATION; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW; SERODIAGNOSIS; WHITE MATTER;

AGING; AIDS DEMENTIA COMPLEX; BRAIN; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS;

EID: 34948871934     PISSN: 17601703     EISSN: None     Source Type: Journal    
DOI: 10.1684/pnv.2007.0093     Document Type: Review

References (80)

1. Moulignier A. Atteintes du système nerveux central et infection par le VIH-1. Rev Neurol (Paris) 2006 ; 162 : 22-42.
2. Navia BA, Jordan BD, Price RW. The AIDS dementia complex : I. Clinical features. Ann Neurol 1986 ; 19 : 517-24.
3. D'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004 ; 55 : 320-8.
4. Jellinger KA, Setinek U, Drlicek M, Böhm G, Steurer A, Lintner F. Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol (Berl) 2000 ; 100 : 213-20.
5. Morgello S, Mahboob R, Yahoushina T, Khan S, Hague K. Autopsy findings in human immunodeficiency virus-infected population over two decades : influences of gender, ethnicity, risk factors and time. Arch Pathol Lab Med 2002 ; 126 : 182-90.
6. Vallat-Decouvelaere AV, Chrétien F, Lorin de la Grandmaison G, Carlier R, Force G, Gray F. La pathologie du système nerveux central liée au VIH à l'ère des multithérapies. Ann Pathol 2003 ; 23 : 408-23.
7. Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 2006 ; 19 : 358-61.
8. Brew BJ. Evidence of a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004 ; 18 (Suppl 1) : S75-S78.
9. Moulignier A, Girard PM. Principaux traitements anti-VIH : toxicité neurologique et interactions à éviter. Neurologies 2001 ; 4 : 140-4.
10. Surveillance de l'infection VIH-sida en France, 2005. Bulletin épidémiologique hebdomadaire 2006 ; 48 : 371-8.
11. HIV/AIDS surveillance in Europe. European centre for the epidemiological monitoring for AIDS. Med-year report 2006, no 67.
12. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006 ; 57 : 4-7.
13. Nogueras M, Navarro G, Anton E, Sala M, Cervantes M, Amengual M, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis 2006 ; 6 : 159.
14. Anton E, Sala M, Mallolas J, Navarro G, Cervantes M, Gatell JM, et al. Clinical and epidemiological study of a series of HIV-infected patients over 50 year-old. Enferm Infecc Microbiol Clin 2005 ; 23 : 145-8.
15. Mugavero MJ, Castellano C, Edelman D, Hicks CH. Late diagnosis of HIV infection : the role of age and sex. Am J Med 2007 ; 120 : 370-3.
16. Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis 2006 ; 42 : 1449-54.
17. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004 ; 18 : 2029-38.
18. Kaufmann G, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002 ; 16 : 359-67.
19. Wellons M, Sanders L, Edwards L, Bartlett J, Helad A, Schmader K. HIV infection : treatment, outcomes in older and younger adults. J Am Geriatr Soc 2002 ; 50 : 603-7.
20. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992 ; 42 : 1736-9.
21. 1HMRI spectroscopy study of the SIV/macaque model of neuroAIDS. BMC Neurosci 2004 ; 5 : 10.
22. McCrossan M, Marsden M, Carnie FW, Minnis S, Hansoti B, Anthony IC, et al. An immune control model for viral replication in the CNS during presymptomatic HIV infection. Brain 2006 ; 129 : 503-16.
23. Pomerantz RJ. Effects of HIV-1 Vpr on neuroinvasion and neuropathogenesis. DNA Cell Biol 2004 ; 23 : 227-38.
24. Pialoux G, Fournier S, Moulignier A, Poveda JD, Clavel F, Dupont B. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS 1997 ; 11 : 1302-3.
25. Lambotte O, Deiva K, Tardieu M. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 2003 ; 13 : 95-103.
26. Wallace DR. HIV neurotoxicity : potential therapeutic interventions. J Biomed Biotechnol 2006 ; 2006 : 1-10.
27. Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE. Upregulation of microglia in drug users with and without presymptomatic HIV infection. Neuropathol Appl Neurobiol 1999 ; 25 : 369-79.
28. Arango JC, Simmonds P, Brettle RP, Bell JE. Does drug abuse influence the microglial response in AIDS and HIV encephalitis. AIDS 2004 ; 18 (Suppl. 1) : S69-S74.
29. Working group of the American academy of neurology AIDS task force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology 1991 ; 41 : 778-85.
30. The Dana consortium on therapy for HIV dementia and related cognitive disorders. Clinical confirmation of the American academy of neurology algorithm for HIV-1-associated cognitive/motor disorder. Neurology 1996 ; 47 : 1247-53.
31. th ed DSM-IV. Washington : APA Press, 1994.
32. Nath A, Berger J. HIV Dementia. CNS Infection 2004 ; 6 : 139-51.
33. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002 ; 8 (Suppl. 2) : 115-21.
34. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999 ; 13 : 1249-53.
35. Welch K, Morse A. The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy. AIDS patients Care STD 2002 ; 16 : 75-81.
36. Scaravilli F, Bazille C, Gray F. Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol 2007 ; 17 : 197-208.
37. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bachetti P, Price RW, et al. HIV-related neuropathology, 1985 to 1999 : rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002 ; 31 : 171-7.
38. Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999 ; 52 : 607-13.
39. Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried MW, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006 ; 20 : 1591-5.
40. Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals : prevalence and potential mechanisms. AIDS 2004 ; 18 (Suppl. 1) : S79-S86.
41. Becker JT, Lopez O, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 2004 ; 18 (Suppl 1) : S11-S18.
42. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, et al. Higher frequency of dementia in older HIV-1 individuals. Neurology 2004 ; 63 : 822-7.
43. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, et al. Neurocognitive dysfunction predicts post mortem findings in HIV encephalitis. Neurology 2002 ; 59 : 1563-7.
44. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988 ; 158 : 1079-83.
45. Wilkie FL, Goodkin K, Khamis I, van Zuilen MH, Lee D, Lecusay R, et al. Cognitive functioning in younger and older HIV-1-infected adults. J Acquir Immune Defic Syndr 2003 ; 33 : S93-S105.
46. Wenserski F, von Giesen HJ, Wittsack HJ, Aulich A, Arendt G. Human immunodeficiency virus 1-associated minor motor disorders : perfusion-weighted MR imaging and 1H MR spectroscopy. Radiology 2003 ; 228 : 185-92.
47. Ances BM, Ellis RL. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007 ; 27 : 86-92.
48. McArthur JC. HIV dementia : an evolving disease. J Neuroimmunol 2004 ; 157 : 3-10.
49. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003 ; 17 : 1539-45.
50. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras : a combined study of two cohorts. J Neurovirol 2004 ; 10 : 350-7.
51. Li ST, Matsushita M, Moriwaki A, Saheki Y, Lu YF, Tomzawa K, et al. HIV-1 inhibits long-term potentiation and attenuates spatial learning. Ann Neurol 2004 ; 55 : 362-71.
52. Riedel DJ, Pardo CA, McArthur J, Nath A. CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006 ; 2 : 557-65.
53. Gray F, Bazille C, Addle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in AIDS patients receiving highly active antiretroviral treatment. J Neurovirol 2005 ; 11 (Suppl. 3) : 16-22.
54. Miller RF, Isaacson PG, Hall-Craggs M, Lucas S, Gray F, Scaravilli F, et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol (Berl) 2004 ; 108 : 17-23.
55. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002 ; 16 : 1019-29.
56. Venkataramana A, Pardo CA, McArthur JC, Kerr DA, Irani DN, Griffin JW, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006 ; 67 : 383-8.
57. Gelman BB, Schuenke K. Brain aging in acquired immunodeficiency syndrome : increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. J Neurovirol 2004 ; 10 : 98-108.
58. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998 ; 65 : 29-33.
59. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005 ; 19 : 407-11.
60. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active antiretroviral therapy. Acta Neuropathol (Berl) 2006 ; 111 : 529-38.
61. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005 ; 19 : 127-35.
62. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes A, et al. Age, apolipoprotein E4, and the risk of HIV dementia : the Hawaii Aging with HIV Cohort. 1. J Neuroimmunol 2004 ; 157 : 197-202.
63. Valcour VG, Shikuma CM, Shiramizu BT, Williams AE, Watters R, Poff PW, et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005 ; 38 : 31-6.
64. Valcour VG, Sacktor NC, Paul RH, Watters MR, Selnes OA, Shiramizu BT, et al. Insulin resistance is associated with cognition among HIV-1-infected patients : the Hawaii Aging With HIV cohort. J Acquir Immune Defic Syndr 2006 ; 43 : 405-10.
65. The Writing Committee of the D:A:D Study Group. Cardio- and cerebro- vascular events in HIV-infected persons. AIDS 2004 ; 18 : 1811-7.
66. Moulignier A. Cerebrovascular disease in HIV-infected patients. In : Barbaro G, Boccara F, eds. Cardiovascular disease in AIDS. Milan : Springer, 2005 : 71-84.
67. Tardieu M, Boutet A. HIV-1 and the central nervous system. Curr Top Microbiol Immunol 2003 ; 265 : 183-95.
68. Toledo Tamula MA, Wolters PL, Walsek C, Zeichner S, Civitello L. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics 2003 ; 112 : 679-84.
69. Cysique LAJ, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006 ; 66 : 1447-50.
70. Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005 ; 19 : 45-52.
71. Wojna V, Nath AN. Challenges to the diagnosis and management of HIV dementia. AIDS Read 2006 ; 16 : 615-32.
72. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, et al. HNRC group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004 ; 56 : 416-23.
73. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence in HIV-infected adults : effect of patient age, cognitive status, and substance abuse. Neurology 2002 ; 59 : 1944-50.
74. Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Marion SD, et al. Age-associated predictors of medication adherence in HIV-positive adults : health beliefs, self-efficacy, and neurocognitive status. Health Psychol 2007 ; 26 : 40-9.
75. Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007 ; 64 : 97-102.
76. De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002 ; 59 : 342-7.
77. Sacktor N, Tarwater PM, Skolasky RL, McArthur JC, Selnes OA, Becker J, et al. Multicenter for AIDS Cohort Study (MACS). CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001 ; 57 : 542-4.
78. Alisky JM. Could Cholinesterase inhibitors and memantine alleviate HIV dementia? J Acquir Immune Defic Syndr 2005 ; 38 : 113-4.
79. Manji H, Miller R. The neurology of HIV infection. J Neurol Neurosurg Psychiatry 2004 ; 75 (Suppl. 1) : i29-i35.
80. Anderson ER, Gendelman HE, Xiong H. Memantine protects hippocampal neuron function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci 2004 ; 24 : 7194-8.